Greenwich LifeSciences rises as trial shows lower breast cancer return rate

Shares of biotech firm Greenwich LifeSciences GLSI.O rise 6.6% to $29.99 premarket

Co says its experimental drug GLSI-100 cut the risk of breast cancer coming back in an ongoing late‑stage study

The annual cancer return rate was under 1% in 250 patients who completed the primary injections, co says

Adds annual cancer return rate was about 4% a year in a similar group treated with standard drug Kadcyla in an earlier study

Data tracked over about 1.2 years in the ongoing GLSI-100 study implies an 83% drop in recurrence; most patients had prior Kadcyla - GLSI

Co adds results are preliminary and will be updated as the study continues

GLSI rose ~87% in 2025